NYSE:RMD
ResMed Inc. (RMD)
Financials 
Technical Analysis 
Jun 6, 2026, 12:00 amThis summary was created by AI, based on 5 opinions in the last 12 months.
ResMed Inc. (RMD-N) has shown impressive performance, with multiple experts highlighting its strong growth metrics and market position. The company has consistently beaten earnings expectations for four consecutive quarters, boasting a substantial 37.09% year-over-year EPS growth, alongside an impressive return on equity (ROE) of 25.81%. Despite a current price-to-earnings (PE) ratio of 31.2x, experts note that this is significantly lower than its 2021 peak of 74.5x, suggesting room for upside potential. Notably, ResMed operates within the U.S., which insulates it from international tariff issues, making it a favorable choice for growth-oriented investors. Although the dividend yield is low at 0.76%, the company is viewed as a solid long-term investment with positive momentum and expected forward margins.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium contentResMed has beaten earnings four straight quarters, and its 31.2x PE is nowhere near its 2021 high of 74.5x. However, the street projects a lower future PE of 27.69x. The most recent EPS of $8.91 was 37.09% more than the previous year. Its ROE of 25.81% ranks among the highest in medical equipment where the average is 9.66%. A bonus is that the company operates within the U.S., so is protected from tariffs. Paying a dividend of only 0.76%, ResMed is one for growth, not income.
Premium contentRMD has been showing positive momentum recently, it is nearing in on its all-time highs, and forward margin expansion is expected to be quite positive. Analyst estimates are trending higher, its margins have been growing, and it generats strong free cash flow, which is partly used for dividends, buybacks, and growing the balance sheet. It is trading at a reasonable valuation of 25X forward earnings, and it has structural tailwinds. We would be comfortable buying the name here today for a long-term hold.
Unlock Premium - Try 5i Free
Premium contentPremium content
Premium contentRMD provides cloud based digital medical devices to assist with sleep and respiratory monitoring and treatment — a steady and reliable business model. It trades at 26x earnings and supports a respectable ROE of 25%. We like that cash reserves are growing, while debt is retired and shares bought back. We recommend setting a stop-loss at $190, looking to achieve $271 — upside potential of 22%. Yield 1.0%
(Analysts’ price target is $271.71)Gagdets like Goggle Watch have shown people how poorly they sleep. Resmed makes sleep apnea machines, which sees big, growing demand, and they hold 90% of the market.
(Analysts’ price target is $241.48)
Brendan Caldwell
18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
ResMed Inc. (RMD) Frequently Asked Questions
What is ResMed Inc. stock symbol?
ResMed Inc. is a American stock, trading under the symbol RMD (previously RMD-N on Stockchase) on the New York Stock Exchange (RMD). It is usually referred to as NYSE:RMD or RMD
Is ResMed Inc. a buy or a sell?
In the last year, 4 stock analysts published opinions about RMD (previously RMD-N on Stockchase). 4 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for ResMed Inc..
Is ResMed Inc. a good investment or a top pick?
ResMed Inc. was recommended as a Top Pick by Mike S. Newton, CIM FCSI on 2018-09-25. Read the latest stock experts ratings for ResMed Inc..
Why is ResMed Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is ResMed Inc. worth watching?
4 stock analysts on Stockchase covered ResMed Inc. in the last year. It is a trending stock that is worth watching.
What is ResMed Inc. stock price?
On 2026-06-05, ResMed Inc. (RMD) stock closed at a price of $196.04.
Our PAST TOP PICK with RMD has triggered its stop at $244. To remain disciplined, we recommend covering the position at this time.